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8ABSTRACT
Intrahepatic cholestasis of pregnancy (ICP) is the most common cholestatic 
liver disease during pregnancy. The reported incidence varies from 0.4 to 15% 
of full-term pregnancies. The etiology is heterogeneous but familial clustering 
is known to occur. Here we have studied the genetic background, epidemiol-
ogy, and long-term hepatobiliary consequences of ICP.
In a register-based nation-wide study (n=1 080 310) the incidence of ICP 
was 0.94% during 1987–2004. A slightly higher incidence, 1.3%, was found in 
a hospital-based series (n=5304) among women attending the University Hos-
pital of Helsinki in 1992–1993. Of these 16% (11/69) were familial and showed 
a higher (92%) recurrence rate than the sporadic (40%) cases. In the register-
based epidemiological study, advanced maternal age and, to a lesser degree, 
parity were identifi ed as new risk factors for ICP. The risk was 3-fold higher in 
women >39 years of age compared to women <30 years. Multiple pregnancy 
also associated with an elevated risk. In a genetic study we found no associa-
tion of ICP with the genes regulating bile salt transport (ABCB4, ABCB11 and 
ATP8B1).
The livers of postmenopausal women with a history of ICP tolerated well 
the short-term exposure to oral and transdermal estradiol, although the doses 
used were higher than those in routine clinical use. The response of serum 
levels of sex hormone-binding globulin (SHBG) to oral estradiol was slightly 
reduced in the ICP group. Transdermal estradiol had no effect on C-reactive 
protein (CRP) or SHBG. A number of liver and biliary diseases were found to 
be associated with ICP. Women with a history of ICP showed elevated risks 
for non-alcoholic liver cirrhosis (8.2 CI 1.9–36), cholelithiasis and cholecystitis 
(3.7 CI 3.2–4.2), hepatitis C (3.5 CI 1.6–7.6) and non-alcoholic pancreatitis 
(3.2 CI 1.7–5.7).
In conclusion, ICP complicates around 1% of all full-term pregnancies in 
Finland and its incidence has remained unchanged since 1987. It is familial 
in 16% of cases with a higher recurrence rate. Although the cause remains 
unknown, several risk factors, namely advanced maternal age, parity and mul-
tiple pregnancies, can be identifi ed. Both oral and transdermal regimens of 
postmenopausal hormone therapy (HT) are safe for women with a history of 
ICP when liver function is considered. Some ICP patients are at risk of other 
liver and biliary diseases and, contrary to what has been thought, a follow-up 
is warranted.
9INTRODUCTION
Intrahepatic cholestasis of pregnancy (ICP) is the most common of familial 
cholestatic conditions. It usually manifests in the third trimester of pregnancy 
as skin itching and as elevation of the serum levels of bile acids and liver en-
zymes (Reyes 1997, Lammert et al 2000). The levels of liver transaminases are 
usually 2–10-fold higher than the normal range. Generally, ICP is considered 
to be harmless to the mother, but preterm birth (12–44%) (Fisk 1988, Rioseco 
et al 1994, Glantz et al 2004), fetal distress (10–44%) (Laatikainen et al 1984, 
Fisk 1988, Alsulyman et al 1996, Glantz et al 2004), and intrauterine fetal death 
(1–3%) (Laatikainen et al 1984, Fisk 1988, Alsulyman et al 1996) may ensue. 
Biochemical cholestasis resolves within a couple of days after delivery (Elferink 
2003), but ICP may recur in 40–60% of subsequent pregnancies (Reyes 1997, 
Germain et al 2002). There has been a wide variation in the reported incidence 
of ICP in different countries (0.4–15%) (Abedin et al 1999, Locatelli et al 1999, 
Germain et al 2002); in Finland and Sweden the incidence is 0.54–1.5% (Laa-
tikainen et al 1984, Berg et al 1986, Heinonen et al 1999).
ICP is thought to be the result of insuffi cient liver capacity to metabolize 
high amounts of placenta-derived sex steroids during pregnancy (Reyes 1997, 
Davidsson 1998). The familial occurrence of ICP in some cases suggests he-
reditary susceptibility (Holzbach et al 1983, Reyes et al 1993, Hirvioja et al 
1993, Jacquemin 2001) and the increasing understanding of the genetic back-
ground of cholestatic diseases in general has aroused interest in the search for 
genes and mutations predisposing also to ICP. Moreover, the increased rate of 
cholelithiasis in these women may imply that ICP is not specifi c to pregnancy 
(Reyes 1997). This hypothesis is further supported by data showing that the 
high amounts of synthetic estrogens, eg. previously used oral contraceptives, 
can trigger symptoms and signs of cholestasis in women with a history of ICP 
(Kreek et al 1967, Adlercreutz et al 1964, Drill 1974, Reyes et al 1981).
The present studies were designed to examine the genetic background, epi-
demiology and hepatobiliary consequences of ICP.
10
REVIEW OF THE LITERATURE
Intrahepatic cholestasis of pregnancy is not well defi ned in the medical litera-
ture and several names have been used for the condition. Icterus and pruri-
tus gravidarum, recurrent jaundice of pregnancy, hepatosis gravidarum, and 
cholestasis of gravidarum have all been used as synonyms to the currently 
used intrahepatic cholestasis of pregnancy (ICP) (Reyes 1997) and obstetric 
cholestasis (Williamson et al 2004). Itching of healthy skin with elevated levels 
of liver transaminases and/or bile acids are the diagnostic criteria for ICP. In 
Finland, Sweden and Chile this disease entity has been well-known for a long 
time and in Finland at least three academic theses on ICP have been published 
previously (Ikonen 1964, Ylöstalo 1970, Heikkinen 1982).
1. Physiology of bile acids
Bile acids facilitate excretion, absorption, and transport of fats and sterols in 
the intestine and liver (Trauner et al 2003). Primary bile acids, cholic acid (CA) 
and chenodeoxycholic acid (CDCA), are synthesized from cholesterol by two 
pathways in the hepatocytes (Fuchs 2003). The two molecules are structurally 
very similar, differing by only one hydroxyl group at position 7 (Figure 1). For-
mation of CA through the classic pathway accounts for 90% of the total bile 
acid synthesis, which is up to 0.5g daily. The synthesis is regulated by the mi-
crosomal cholesterol-7α-hydroxylase (CYP7A1), which in turn is regulated by 
the availability of cholesterol and the concentrations of bile acids themselves. 
(Chiang 2003).
Figure 1. Structure of primarybile acids
 
Cholic acid     Chenodeoxycholic acid 
3a7a12a-trihydroxy-5ß-cholanoic acid  3a7a-dihydroxy-5ß-cholanoic acid 
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An alternative pathway leads to the formation of CDCA, where the 7α-hy-
droxylation is preceded by the formation of oxysterols. These are metabolized 
by oxysterol 7α-hydroxylase (CYP7B1) enzyme (Chiang 2003).
The primary bile acids are conjugated in the hepatocytes with glycine or 
taurine to form bile salts, which are actively excreted to the bile through ATP-
dependent membrane transporters (Fuchs 2003). The bile salts are then stored 
in the gallbladder as mixed micelles with phosphatidylcholine and cholesterol.
1.2. Enterohepatic circulation
The enterohepatic circulation ensures effi cient use of synthesized bile acids with 
minimal daily loss (Figure 2). The pool of human bile salts, 2–4g, circulates 3–15 
times per day resulting in 20–40g of daily excretion. Only 3–5% of bile salts (0.5g) 
95%
5% (0.5g/day)
5%(0.5g/day)
Figure 2. Enterohepatic circulation. Primary bile acids are synthesized in the liver and con-
jugated with glycine or taurine. Bile salts are excreted into bile and stored in the gallblad-
der. From the intestine bile acids are transported back to the liver via portal circulation. 
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are lost daily in faeces and are replaced by de novo synthesis from cholesterol. 
(Trauner et al 2003). The fi rst step of the enterohepatic circulation is the excretion 
of bile from the gallbladder to the intestine. This secretion into the duodenum 
occurs after each meal due to vagal stimulation and release of cholecystokinin 
from the mucosa of the duodenum, which causes contraction of the gallbladder. 
(Chiang 2003). In the intestine CA and CDCA are converted to secondary bile
acids, deoxycholic acid (DCA, 3α12α-dihydroxy-5β-cholanoic acid) and litho-
cholic acid (LCA, 3α-monohydroxy-5β-cholanoic acid), by bacteria (Chiang 
2003) (Figure 3). Ursodeoxycholic acid (UDCA, 3α7β-dihydroxy-5β-chola-
noic acid) is also formed by intestinal bacteria. It differs from CDCA by one 
hydroxyl group, which is in the β position at C-7. Only trace amounts of this 
bile acid are present in humans, whereas larger amounts are found at least in 
bears. (Trauner et al 2003, van Mil et al 2005).
Figure 3. Primary and secondary bile acids are synthesized from cholesterol.
CholesterolCholesterol
Cholic acidCholic acid
Chenodeoxycholic
acid
Chenodeoxycholic
acid
Deoxycholic acidDeoxycholic acid Litocholic acidLitocholic acid
Conjugated bile acids are absorbed from the intestine by at least two carrier-
mediated processes (van Mil et al 2005). Bile acids, returned to the liver in 
portal venous blood, are actively taken up by the liver and, once again, secreted 
into the bile thus completing the enterohepatic circulation. The large major-
ity of bile salts (95%) are reabsorbed from the intestine (Pauli-Magnus et al 
2005) (Figure 2 and Table 1). Equal amounts of conjugated CA and CDCA 
(80%), and conjugated DCA (10%) form the main bile acid pool and only 
traces of conjugated LCA and UDCA are present in the bile. Bile salts that es-
cape from the enterohepatic circulation to the systemic circulation are fi ltered 
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through the glomeruli in the kidneys and either reabsorbed from the tubules 
or excreted into urine. Normally the main excretion is through faeces, but in 
cholestatic conditions the amount excreted in urine increases (van Mil et al 
2005). In blood bile salts are bound predominantly to albumin and high-den-
sity lipoproteins (60–85%). The ultimate goal of enterohepatic circulation is to 
ensure that bile salts are rapidly available in suffi cient amounts when needed 
for digestion.
1.3. Transporter mechanisms
Hepatobiliary transport systems mediate hepatic uptake and biliary excretion 
of bile salts. Reduced or totally absent expression of these transporters has an 
important role in cholestasis (Chiang 2003) and for full comprehension of 
cholestatic disorders one must understand their function. 
1.3.1. Transporters on basolateral membranes of hepatocytes
The basolateral membrane of the hepatocyte plays a key role in transporting 
bile acids and salts from venous blood to the liver (Figure 4). This is achieved 
by two major pathways. Firstly, the sodium-dependent sodium-taurocholate 
cotransporting polypeptide NTCP (a member of the solute carrier protein, the 
SLC-gene family, SLC10A1) accounts for more than 80% of conjugated, but 
for less than 50% of unconjugated bile salt uptake (Pauli-Magnus et al 2005). 
Secondly, the sodium-independent organic anion transporting polypeptides 
(OATPs) (members of the SLC-gene family) form another transporter system, 
which also transports bilirubin, bromsulphthalein, steroid sulphates and glu-
Table 1. Bile acids in the enterohepatic circulation.
Amounts produced and circulated
Total pool in body 2–4 g
Daily synthesis 0.5 g
Secretion 4–6 g/meal; 12–40 g/day
Recycling frequency 3–15 times/day
Concentrations
Biliary ductuli 20–50 × 10³µmol/l
Gallbladder up to 300 × 10³µmol/l
Venous blood
  Portal vein
  Systemic circulation
20–50µmol/l
3–5 µmol/l
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Figure 4. 
A) Bile acid transporter proteins. Sodium-taurocholate transporting protein (NTCP), or-
ganic anion transporting polypeptides (OATPs) and transporter for small hydrophilic or-
ganic compounds (OAT/OCT) transport bile acids across the basolateral membrane into 
the hepatocyte. Multidrug resistance protein 3 (MDR3), bile salt export pump (BSEP), 
multidrug associated protein 2 (MRP2), a P-type ATPase FIC1, and halftransporters 
ABCG5/8 transport across canalicular membrane to the bile canaliculi. 
MRPs are transporters of various organic anions, such as bile salts.
B) Schematic presentation of the regulation of intracellular bile acid concentration by 
nuclear receptors. When bile acid (ba) concentration rises in the hepatocyte, Farnesoid 
receptor X (FXR) binds to bile acids and inhibits via small heterodimeric partner (SHP) 
the transcription of CYP7A1 and CYP7B1 enzymes (inhibits synthesis of bile acids) and 
NTCP transporter (decreases uptake), but activates the transcription of  BSEP and MDR3 
(increases excretion). As the result, bile acid concentration decreases in the hepatocyte.
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curonides, neutral steroids, and conjugated and unconjugated bile salts (Pauli-
Magnus et al 2005). Bile acids and salts are highly toxic to cells (van Mill et al 
2005) and they are bound to intracellular proteins in the hepatocytes (Ferenci 
et al 2002), although it is not known exactly how they are transported there. 
Anyway, the basolateral transporters regulate the uptake of bile salts from ve-
nous blood to hepatocytes.
1.3.2. Transporters on canalicular membranes of hepatocytes
The canalicular membrane of the hepatocyte faces the bile ductulus (Figure 
4). The transporter proteins on the canalicular membrane belong to the family 
of ATP-dependent P-glycoproteins (ATP-Binding-Cassette, ABC-superfamily) 
(Lee et al 2000). These include several subgroups of transporter proteins, such 
as multidrug-resistance proteins (ABCB-gene family), multidrug-resistance 
associated proteins (ABCC-gene family), and ABC-halftransporters (ABCG-
gene family) (Pauli-Magnus et al 2005). 
The bile salt export pump (BSEP, ABCB11) is primarily responsible for 
transporting the conjugated bile salts from the hepatocyte to the bile canaliculi. 
The multidrug resistance protein 3 (MDR3, ABCB4) functions as a phospholi-
pid fl ippase translocating phospholipids from the inner to the outer leaf of the 
canalicular membrane (Pauli-Magnus et al 2005) (Figure 4). A P-type ATPase, 
the FIC1-protein (ATP8B1), is involved in bile acid transport. Its function is 
not well understood, but it is an ATP-dependent aminophospholipid trans-
porter and thought to play a role in the regulation of the bile acid pool. (Pauli-
Magnus et al 2005).  The multidrug resistance-associated protein 2 (MRP2, 
ABCC2) is the only member of this MRP subgroup which is located on the 
canalicular membrane while the other MRPs are on the basolateral membrane 
(Pauli-Magnus et al 2005). It transports bile salt conjugates, bilirubin diglu-
curonide, and glutathione conjugates. Halftransporters ABCG5 and ABCG8 
are also expressed in the canalicular membrane and participate in cholesterol 
and plant sterol excretion (Yu et al 2002). Taken as a whole, the basolateral and 
canalicular membranes contain many transporter proteins which regulate bile 
acid and cholesterol homeostasis in man and which, if defective or absent, lead 
to cholestasis.
1.3.3. Intestinal transporters
Bile acids and salts are actively transported in the intestine. In the terminal 
ileum, the apical membrane of the enterocytes contains sodium-dependent 
bile salt transporters (SLC10A2). In the enterocytes, bile acid-binding protein 
transports bile acids to the basolateral membrane (van Mil et al 2005).The 
mechanism of bile salt transport to the venous blood and portal circulation is 
unknown (Pauli-Magnus et al 2005). A multidrug resistance-associated pro-
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tein, MRP3, is expressed in the basolateral membrane of enterocytes (Pauli-
Magnus et al 2005), and is a candidate transporter for this.
1.3.4. Regulation
The intracellular concentration of bile acids in the hepatocytes is tightly regulated 
as bile acids are highly toxic due to their detergent properties. The synthesis and 
excretion of bile acids and salts are controlled by their concentration in blood and 
hepatocytes. In response to high bile acid concentration, both the synthesis and 
absorption in the hepatocyte decrease while the secretion into the bile increases 
(van Mill et al 2005). Regulation of these processes is mediated by transcription 
factors called nuclear hormone receptors, which can activate or inactivate the 
transcription of relevant genes (Figure 4). Farnesoid X receptor (FXR), when 
bound to bile acids, activates the transcription of short heterodimeric partner 
(SHP), which leads to inactivation of the rate limiting step in bile acid synthesis 
(CYP7A1 and CYP7B1 enzymes) (Figure 4). At the same time, bile salt absorp-
tion decreases from the capillary venous blood, because SHP also inhibits the 
expression of the NTCP-pump in the basolateral membrane. (Pauli-Magnus et 
al 2005, van Mil et al 2005). In contrast, the transcription of BSEP and MDR3 is 
increased by FXR, enhancing the excretion of bile acids. Thus, the concentration 
of bile acids in the hepatocyte is decreased by all these mechanisms. On the oth-
er hand, liver X Receptor reacts to high cholesterol levels in the hepatocyte and
CYP7A1 enzyme is induced to convert cholesterol to bile acids. (van Mil et al 
2005). Summing up, the homeostasis of bile acids and cholesterol is effi ciently 
regulated in the hepatocytes, but the complex regulatory mechanisms are still 
incompletely understood.
2. Intrahepatic cholestasis
Cholestasis is defi ned as an impairment of bile secretion due to intrahepatic 
or extrahepatic causes. Any diseases which lead to failure in the synthesis or 
decreased excretion of bile acids within the liver can result in cholestasis (Bal-
istreri et al 2005). Extrahepatic cholestasis is caused by any obstructing factor 
in the bile ducts outside the liver, of which cholelithiasis and pancreatic tumors 
are the two most common. Normally the ratio of bile salts bound to glycine or 
taurine is 3:1, but in cholestasis the concentrations of sulphate and glucuro-
nide conjugates increase (Lammert et al 2000). Likewise, excretion of bile salts 
through the kidneys increases in cholestasis, which may explain the increased 
amounts of sulphate and glucuronide conjugates in urine (Trauner et al 2003). 
The ratio of CA to CDCA is normally less than 1.5, but it increases in cholestatic 
conditions (Lammert et al 2000). The increased concentration of bile acids in 
cholestasis inhibits their synthesis. This in turn leads to the accumulation of 
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cholesterol and hypercholesterolemia may ensue. (Chiang 2003). Lipoprotein X 
is an abnormal, low density lipoprotein which is present only in patients with 
cholestasis (Jacquemin 2001). These changes are typical to cholestasis, regard-
less of the causative factor (Chiang 2003), and explain how the synthesis and 
homeostasis of bile acids and cholesterol are intertwined with each other and 
contribute to the clinical phenotypes. 
2.1. Intrahepatic cholestatic diseases
Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are 
the major chronic cholestatic diseases. Their prevalence is approximately 5 and 
3 per 100 000, respectively, and over 90% of PBC patients are women (Kowdley 
2000). Both diseases progress slowly to cirrhosis. It is established that infl am-
matory factors are important in PBC and PSC and that in PSC the large and 
medium sized bile ductuli are destroyed while in PBC the small bile canaliculi 
are affected (Kowdley 2000). The risk of PBC is nearly 100-fold elevated in the 
fi rst-degree relatives of patients (Parikh-Patel et al 1999). No genetic defect has 
been found so far either in PBC or PSC (Pauli-Magnus et al 2005).
Sepsis and several viruses, such as Ebstein-Bar, cytomegalo, herpes and hep-
atitis, may also cause cholestasis (Elferink 2003, Hinedi et al 2003). This may be 
a refl ection of infection-infl ammation cascade. In hepatitis C the down-regu-
lation of the MRP2 expression may also be involved. (Hinoshita et al 2001).
The mechanism, by which drugs and alcohol induce cholestasis, is not 
known. They may inhibit the BSEP-pump, thus impairing the excretion of bile 
salts from the hepatocyte (Pauli-Magnus et al 2005), but they also impair the 
expression of NTCP and OATPs, decreasing the uptake of bile salts from the 
systemic circulation (Zollner et al 2001). As briefl y described above, much is 
known of the causes and development of intrahepatic cholestasis, but the regu-
latory mechanisms behind these phenomena are still poorly understood.  
2.2. Familial cholestatic diseases 
Familial intrahepatic cholestases comprise a group of diseases which are mostly 
quite rare (Table 2). These include defects of synthesis and transport of bile ac-
ids (Jacquemin 2001, van Mil et al 2005) and some other rare conditions (Table 
2). Mutations behind this heterogeneous group of familial diseases have been 
identifi ed in recent years (Pauli-Magnus et al 2005). Some of them (such as be-
nign recurrent intrahepatic cholestases, BRICs) are mild with long, symptom-
free periods intervening with recurrences. Others are serious illnesses (such 
as progressive familial intrahepatic cholestases, PFICs) leading to progressive 
liver failure and cirrhosis and may necessitate liver transplantation already in 
childhood (Jacquemin 2001). Defects in the canalicular transporters (Figure 4) 
include three subtypes of recessively inherited progressive familial intrahepatic 
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cholestases (PFIC1, PFIC2 and PFIC3) and two subtypes of benign recurrent 
intrahepatic cholestasis (BRIC1 and BRIC2). Cholestasis presenting already 
during the fi rst year of life is characteristic for all PFIC types (Table2) (Jac-
quemin 2001). In PFIC types 1 and 2 concentrations of bile salts in serum are 
high, while the levels of cholesterol and gamma-glutamyl transferase (GT) are 
normal. Steatorrea, diarrhea and jaundice belong to clinical features of PFIC1 
(Pauli-Magnus et al 2005). These symptoms are not present in patients with 
PFIC2. Mutations in the ATP8B1 gene encoding the FIC1 transporter cause 
PFIC type 1 and cause total or almost total absence of functional FIC1 protein 
on the canalicular membrane (Figure 4) (Pauli-Magnus et al 2005, van Mil et 
al 2005). The same protein is also expressed on the cell membranes in the in-
testine, pancreas and biliary tract cholangiocytes. This may explain the occur-
rence of pancreatitis and diarrhea in these patients (Pauli-Magnus et al 2005). 
Mutations in the BSEP, coded by ABCB11, cause decreased bile salt export to 
the bile canaliculus in PFIC type 2 patients.
Only the liver is affected in PFIC type 3 and these patients have high levels 
of gamma GT (Jacquemin 2001). Phospholipids, which are important in the 
formation of micelles in biliary canaliculi, are partly or totally missing from 
bile in this disease depending on the type of mutation in the ABCB4 gene en-
coding the MDR3 protein. Bile ducts are thus proliferated and typically these 
patients have jaundice, itching, hepatosplenomegaly, portal hypertension and 
ultimately liver function fails (van Mil et al 2005). 
It has been thought that BRIC diseases are clinically benign diseases. They 
typically begin in adulthood with recurrent periods of cholestasis. Mutations 
in BRIC types 1 and 2 are in the same genes, ATP8B1 and ABCB11, which 
cause PFIC types 1 and 2. The differences of the mutations with varying re-
sidual function seem to explain the varying phenotypes especially in PFIC1 
and BRIC1 patients. (Pauli-Magnus et al 2005).  A later developing progressive 
cholestasis has also been reported in patients who were thought to have the 
benign type of the disease. Cholelithiasis is associated with ABCB11 gene mu-
tations in BRIC2 patients. As in BRIC1 some patients with BRIC2 manifest a 
more aggressive type of disease later in life (van Mil et al 2005). Not all families 
segregating the BRIC phenotype have mutations in these two genes, suggest-
ing a third locus (Pauli-Magnus 2005). As we have seen different mutations in 
genes encoding the transporting proteins of bile acids lead to cholestasis. 
21
3. Liver during pregnancy
Although human pregnancy is accompanied by signifi cant changes in cardio-
vascular and other physiology, the liver and its function show relatively small 
alterations in normal pregnancy (Scherlock 1985). The size of the liver and its 
blood fl ow do not differ from those in the non-pregnant state. In liver biopsy, 
only mild lymphocytic infi ltration of the portal zones can be seen, but there are 
no changes specifi c for pregnancy. (Scherlock 1985). However, teleangiectasias 
and palmar erythema, which can be markers of liver dysfunction in non-preg-
nant subjects, may appear in up to 60% of normal pregnancies without any 
evidence of liver disease (Knox 1998). The increasing levels of progesterone 
may relax the smooth muscle of the gallbladder, which does not contract ef-
fi ciently during pregnancy (Riley 1992). 
Changes seen in the function of the liver during normal pregnancy include 
reduced clearance of bromsulphtalein during the last trimester (Simcock et al 
1967, Fulton et al 1983). Additionally the synthesis of albumin decreases pro-
gressively, and its level in serum is around 30% lower at term as in non-pregnant 
women; this can of course be partly due to the relative hemodilution (Branch 
1992). Likewise, the synthesis of globulins decline but not as much as albumin 
and therefore the albumin/globulin ratio decreases. Estrogen increases the syn-
thesis of several proteins in the liver such as fi brinogen and ceruloplasmin, and 
the binding proteins for corticosteroids, sex steroids, and thyroid hormones. 
Increased fi brinogen concentrations result in the elevation of the erythrocyte 
sedimentation rate. (Branch 1992). Total and LDL-cholesterol levels increase 
by approximately 25% and 34%, respectively, from baseline to week 36 during 
normal pregnancy (Amundsen et al 2006). The levels of bile acids and liver 
transaminases do not change during normal pregnancy, but serum alkaline 
phosphatase levels rise mainly due to leakage of placental alkaline phosphatase 
(Laatikainen 1977, Carter 1991, Bacq et al 1996). However, the bile acid pool in 
fetal serum at term differs from the maternal pool. During normal pregnancy 
the main bile acid in the fetus is CDCA (Laatikainen 1977). Because in mater-
nal blood the ratio of CA to CDCA is less than 1.5, the placenta maintains a 
concentration gradient for these bile acids between maternal and fetal plasma. 
Recently, some bile acid transporter proteins, namely MDR3, FIC1, and two 
members of OATP-protein family, have been found to be expressed in placenta 
(Patel et al 2003). Although OATPs and FIC1 are down-regulated in the third 
trimester, MDR3 protein expression is up-regulated four-fold compared to the 
fi rst trimester of normal pregnancy (Patel et al 2003). 
3.1. Intrahepatic cholestasis of pregnancy
The most common form of intrahepatic cholestatic condition in general is ICP 
and it is the most common liver disorder during pregnancy.
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3.1.1. Epidemiology
The incidence of ICP shows large variation between different countries and 
populations (Lammert et al 2000). In Finland and Sweden, ICP occurs in ap-
proximately 1.0–1.5% of pregnancies (Laatikainen et al 1984, Berg et al 1986) 
while in other European countries the incidences have been lower e.g. in France 
and Italy 0.4–1% (Reyes 1997, Locatelli et al 1999, Roncaglia et al 2002). In the 
United Kingdom, ICP affects only 0.6% of pregnancies in white Caucasians, 
but 1.4% of pregnancies of Indian and Pakistani origin (Abedin et al 1999), 
suggesting ethnic origin as one determinant of the risk. The highest incidence 
of ICP (14%) has been reported from Chile (Reyes 1997), but a much lower in-
cidence (2–4%) was found in the latest report (Germain et al 2002). The vary-
ing incidences may be explained by differences in diagnostic criteria, genetic 
background, or in the environment.
Multiple pregnancy increases the risk of ICP 5-fold (Gonzalez et al 1989, 
Glantz et al 2004). The recurrence of ICP has been noted in 40–60% of patients 
(Reyes 1997). The data available so far imply that there are three risk factors for 
ICP multiple pregnancy, positive family history and a previous pregnancy with 
ICP (Davison 1998).
3.1.2. Pathogenesis
In spite of extensive studies, the cause of ICP is still unknown. Yet it is com-
monly accepted that ICP could be the result of a relative incapacity of the liver 
to metabolize the high amounts of placenta-derived steroids during pregnancy 
(Reyes 1997). This is also supported by data showing that multiple pregnancies 
with higher steroid loads predispose to ICP (Laatikainen et al 1984, Gonzalez 
et al 1989, Glantz et al 2004). Accordingly, the previously used high-dose oral 
contraceptives have been shown to trigger cholestasis in women with a history 
of ICP (Kreek et al 1967, Adlercreutz et al 1964, Drill 1974, Reyes et al 1981). 
The liver histology in ICP reveals only dilated bile canaliculi without little or 
no evidence of hepatocellular change and no infl ammatory reaction.
3.1.3. Genetics
A genetic background is suggested by the familial occurrence of ICP. Several 
published pedigrees support the dominant mode of inheritance (Holzbach et 
al 1983, Hirvioja et al 1993, Eloranta et al 2001). The observation that het-
erozygous mothers of children with recessively inherited progressive familial 
intrahepatic cholestasis type 3 (PFIC3) had experienced ICP during pregnancy 
implies that the genetic background, namely ABCB4 gene mutations, exists for 
ICP in these families (Dixon et al 2000, Jacquemin 2001, Gendrot et al 2003, 
Lucena et al 2003, Müllenbach et al 2003). A tendency to gallstone disease in 
these heterozygous parents could be explained by high cholesterol and low 
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phospholipid concentrations in bile. A tendency to develop ICP was proposed 
to be associated with a specifi c ABCB11 allele (Eloranta et al 2003), although 
later studies did not confi rm this (Painter et al 2004). Recently, several variants 
of the ATP8B1 gene (encoding the FIC1 protein) have been detected in women 
with ICP (Painter et al 2005, Müllenbach et al 2005), but the signifi cance of 
these fi ndings is still uncertain. Presently ICP is classifi ed as a cholestatic con-
dition with defective bile acid transport, as is the case for those few patients in 
whom the molecular genetic background has been identifi ed, but other disease 
mechanisms are also possible.  
3.1.4. Clinical picture and treatment
Typically ICP manifests in the third trimester with itching, which starts on the 
soles and palms. Subsequently it extends to the extremities and trunk, and is 
usually aggravated during the night disturbing sleep. Levels of liver transami-
nases in serum are usually 2–10-fold increased and bile acids may be up to 100 
times higher than the normal range (Reyes 1992). Typically, the levels of CA 
are at least twice as high as the levels of CDCA (Heikkinen et al 1981, Brites 
et al 1998) and taurine conjugates are increased. The glycine/taurine ratio in 
maternal blood during pregnancy with ICP is half of that in normal pregnancy 
(Brites et al 1998). Total and LDL-cholesterol concentrations are higher during 
pregnancy with ICP than in normal pregnancy (Dann et al 2006).
No anatomical changes have been detected in the liver or biliary tract com-
pared to non-pregnant fi ndings in ultrasonography. Biochemical cholestasis 
resolves in a couple of days after delivery (Elferink 2003).
To the mother ICP does not impose a risk (Reyes 1997). However, it is as-
sociated with increased fetal risks such as preterm birth (12–44%) (Fisk et al 
1988, Rioseco et al 1994, Glantz et al 2004), fetal distress (10–44%) (Laatikai-
nen et al 1975, 1984, Fisk et al 1988, Alsulyman et al 1996, Glantz et al 2004), 
or death of the fetus (1–3%) (Laatikainen et al 1975, Fisk et al 1988, Alsulyman 
et al 1996). It is not known by which mechanism ICP endangers fetal wellbe-
ing, but in autopsies of stillbirth, signs of acute asphyxia (petechial bleeding in 
lungs, pericardium, and adrenal glands) are seen. Placental histology reveals 
only non-specifi c changes. (Williamson et al 2004). It has been proposed that 
maternal levels of bile acids exceeding 40µmol/l could be used as a marker 
of possible fetal risk (Glantz et al 2004). Although there is discrepancy over 
whether the fetal distress is the result of high levels of bile acids in the fetal 
blood (Laatikainen 1977, Heikkinen et al 1980, Shaw et al 1982, Alsulyman 
et al 1996, Laatikainen et al 1984), the levels of bile acids in fetal serum and 
amniotic fl uid are higher in ICP than in normal pregnancies (Laatikainen et 
al 1978, Rodrigues et al 1999). One mechanism by which bile acids conjugated 
with taurine could endanger fetal well-being is their arrhythmogenic effect on 
the fetal cardiac myocyte function (Gorelik et al 2004). 
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Various medications, such as antihistamines and benzodiazepines, have 
been used to relieve the itching. These do not affect the bile acid levels in the 
serum. Phenobarbital, when used for treatment, can induce the hepatic micro-
somal enzymes and thereby it may increase the excretion of bile acids (Davids-
son 1998). Intravenous S-adenosylmethionine (Frezza et al 1990, Ribalta et al 
1991, Nicastri et al 1998), oral dexamethasone (Hirvioja et al 1992, Glantz et al 
2005), cholestyramine (Laatikainen 1978, Heikkinen et al 1982), and guar gum 
(Riikonen et al 2000) have been shown to reduce the levels of bile acids or to 
relieve itching. Most studies have been small and there is insuffi cient evidence 
of the benefi ts (Burrows et al 2001).
A naturally occurring hydrophilic bile acid UDCA modifi es the bile acid 
pool. It is widely used in treatment of cholestatic diseases in general (James 
1990). The concentrations of CA and CDCA decrease during UDCA treatment 
both in maternal and cord blood, in amniotic fl uid and in colostrum (Brites et 
al 1998, Berkane et al 2000, Mazzella et al 2001) but not in the meconium. In 
enterohepatic circulation UDCA replaces the CA and CDCA and CA/CDCA 
ratio returns to the same level as in normal pregnancy (Brites et al 1998). Dur-
ing treatment, the concentration of UDCA increases in the maternal serum, 
but only very slightly in the amniotic fl uid (Mazzella et al 2001). In hepatocytes 
UDCA binds to FXR thereby decreasing the synthesis of bile acids and increas-
ing excretion.
Tauroconjugates of bile acids, which are increased in ICP patients (Brites et 
al 1998), are also decreased during UDCA treatment. No maternal or fetal side 
effects have been described (Davies et al 1995, Davidsson 1998, Burrows et al 
2001).
Fetal surveillance is necessary in pregnancies with ICP, at least at an outpa-
tient clinic, as is the use of UDCA to lower the bile acid levels. Clinically, the lev-
els of liver transaminases and bile acids are determined routinely once or twice 
weekly and fetal cardiotocography recorded weekly or even daily, depending on 
the bile acid levels in the maternal blood. Yet a normal fetal heart rate does not 
guarantee fetal well-being (Alsulyman et al 1996, Sentilhes et al 2006). As clini-
cians do not have a totally reliable test for fetal risks, labour is often induced 1-2 
weeks before term.
3.1.5. Associated hepatobiliary disorders
Although it has been established that a history of ICP predisposes to gallstone 
disease (Reyes 1997), other hepatobiliary consequences of ICP are scarcely 
known. It is of course possible that in some ICP cases an early form of PBC 
may have been present and misdiagnosed as ICP (Leevy et al 1997, Reyes 1997, 
Lucena et al 2003). It has also been reported that the incidence of ICP is el-
evated in women with hepatitis C (Locatelli et al 1999) but this fi nding has not 
been confi rmed by others. Thus, except for an elevated risk of cholelithiasis, al-
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most no data exist on the subsequent hepatobiliary or other diseases in women 
with a history of ICP.
3.2. Other liver diseases and pregnancy
Many chronic liver diseases do not prevent pregnancies and therefore, preg-
nancies may be accompanied by these. Pruritus, nausea, jaundice, and acute 
abdominal pain during pregnancy all necessitate the testing of liver function 
and a search for the cause.
Pregnancy does not alter the course of hepatitis A, B or C (Floreani et al 
1996, Hunt et al 1999). Hepatitis C, however, may be associated with ICP or an 
ICP-like condition (Locatelli et al 1999). Liver cirrhosis impairs fertility and, 
in case of a pregnancy, the risk of spontaneous abortion, hypertension, pre-ec-
lampsia, and preterm birth may be increased (Armenti et al 2000). Pregnancy 
may also deteriorate the prognosis of cirrhosis (Marinaccio et al 1992, Armenti 
et al 2000). Inherited disorders of bilirubin metabolism are characterized by el-
evated levels of serum conjugated or unconjugated bilirubin and they may fur-
ther elevate during pregnancy especially in Dubin-Johnson syndrome, which 
is caused by defective function of the MRP2 (Knox 1998, Keppler et al 2000). 
Pregnancy does not, however, impair the liver function or prognosis of these 
patients. 
Cholelithiasis may naturally occur at any time during pregnancy, and preg-
nancy itself predisposes to cholelithiasis. It is known that 6–12% of women 
have asymptomatic gallstones immediately after delivery (Valdivieso et al 1993, 
Hunt et al 1999). Severe pre-eclampsia may also be accompanied by changes 
in the liver function (Knox et al 1996). Hemolysis, elevated liver enzymes, and 
a low platelet count constitute the HELLP syndrome accompanied with other 
symptoms of pre-eclampsia.
Acute fatty liver of pregnancy affects 1 in 13 000 pregnancies and occurs 
typically during the third trimester (Knox et al 1996, Hunt et al 1999). A he-
matoma or rupture of the liver are encountered very rarely (1 in 40 000–250 000 
pregnancies) (Hunt et al 1999). Acute hemorrhage and subcapsular hematoma 
of the liver are usually associated with severe pre-eclampsia (80%), but tumors 
and abscesses can also predispose to their occurrence (Knox 1998). 
Severe liver diseases during pregnancy are not common, but they are clini-
cally important as many of them are serious diseases which may even have fatal 
outcomes.
26
4. Postmenopausal hormone therapy and liver proteins
With increasing age the size of the liver and also its blood fl ow decreases and 
the repair of damaged cells is slower than in younger people. The synthesis of 
albumin does not change and the levels of liver transaminases stay within the 
normal range. The production and fl ow of bile decrease and this may contrib-
ute to the increased risk of gallstone formation. (Vuoristo 2001).
Hormone therapy (HT), estrogen alone (ET) or in combination with pro-
gestin (EPT), is commonly used to alleviate postmenopausal vasomotor symp-
toms (MacLennan et al 2002). These regimens are usually administered orally 
or transdermally, although estrogens can be given also intranasally, subcutane-
ously or intramuscularly (Samsioe 2002). Estrogens and progestins given orally 
undergo the fi rst pass metabolism in the liver, whereas when given parenter-
ally these hormones escape this step (Nachtigall 1995). After oral administra-
tion of estradiol (E2) approximately 70% is metabolized in the liver to estrone 
(E1), which is the main circulating estrogen during oral treatment. Further 
breakdown happens through two major pathways, which result in metabolites 
with decreasing activity, namely estriol (E3) and cathecol-estrogens (Samsioe 
2002). In the liver E1 and E2 are conjugated mainly to glucuronide and sulfate 
and excreted through bile to the intestine, where they are deconjugated and 
80% are reabsorbed into blood. Only a minor proportion (1–2%) of E1 and 
E2 circulate as free hormones, because they are bound to SHBG (40%), and to 
albumin (58%) (Dunn 1981, Plowchalk 2002). 
The main circulating estrogen during transdermal E2 administration is E2 
(Samsioe 2002). Transdermal HT does not affect the hepatic metabolism (Se-
rin et al 2001). Whether postmenopausal HT affects liver function and the pro-
duction of CRP and SHBG in women with a history of ICP is unknown.
4.1. Sex hormone-binding globulin 
The synthesis of SHBG occurs in the liver (Jänne et al 1998). Plasma SHBG 
regulates the bioavailable fraction of steroids and also their access to target 
cells (Hryb et al 1990, Rosner et al 1991, Kahn et al 2002). The gene coding 
for SHBG resides in chromosome 17 and hepatocyte nuclear factor-4 controls 
the transcription (Jänne et al 1998). Mutations in this gene result in decreased 
excretion of SHBG (Hogeveen et al 2001, 2002). Estrogen and thyroid hor-
mones increase, while androgens decrease the synthesis of SHBG (Anderson 
1974, Loukovaara et al 1995, Nachtigall et al 2000). Hyperinsulinemia, insulin-
like growth factor-1 (IGF-1) and hyperandrogenism are associated with low 
circulating SHBG (Pugeat et al 1995, Kalme et al 2003, Hogeveen et al 2002). 
Falling levels of estrogens are thought to explain the decrease in the levels of 
SHBG after menopause (Sarrel 2002). 
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Use of oral ET elevates the concentrations of SHBG (Samsioe 2002). Trans-
dermal ET, however, has no effect on SHBG levels according to most stud-
ies (Steingold KA et al 1991, Nachtigall et al 2000, Samsioe 2002), although 
small increases in SHBG levels have been reported (Kramer et al 2003). The 
effect of a progestin on serum SHBG levels depends on the androgenicity of a 
given therapy (Nugent et al 2003). Androgenic progestins, e.g. norethisterone 
acetate, decrease the synthesis of SHBG, whereas cyproterone acetate and dy-
drogesterone have no effect (Nugent et al 2003). Changes in SHBG concentra-
tions during HT use may be of clinical signifi cance because the higher the level 
of SHBG the smaller the biologically active free fraction of estrogen (Samsioe 
2002). This may determine, at least in part, the clinical consequences of estro-
gen use, both desired and undesired. 
4.2. C-reactive protein 
During the last few years CRP has become a focus of intense research in meno-
pause. This protein has been used for years as a marker of infection or infl am-
mation. In the tissue, infection causes the release of cytokines which then enter 
the liver stimulating the synthesis of CRP (Straub et al 2000). Recent data have, 
however, suggested that even subclinical elevations in the concentration of 
CRP may predict the risk of cardiovascular disease (Koenig et al 1999, Ridker et 
al 2000). This effect could be mediated through activation of the complement 
cascade in atherosclerotic plaques in blood vessels, which may ultimately result 
in a thrombosis-like event in arterial walls (Lagrand et al 1999).
Long-term use of oral HT has been associated with elevated levels of CRP 
whereas transdermal HT has had no effect (Table 3). It has been thought that 
this CRP rise may be responsible for the negative effects of HT in the trials 
where oral HT has been given either for primary (Manson et al 2003) or sec-
ondary (Hulley et al 1998) prevention of cardiovascular diseases. It is diffi cult 
to explain why oral HT raises CRP because the synthesis of cytokine interleu-
kin 6 (IL-6), the main stimulator of CRP synthesis, does not increase during 
oral HT. (Lakoski et al 2005). Although much data have been collected on CRP 
during HT use, we still do not know how soon the effect of oral HT becomes 
detectable or whether it is strictly dependent on the dose of estrogen (Lakoski 
et al 2005). Moreover, the effect of progestin on CRP is less clear and, fi nally, no 
data exist on the impact of HT on CRP in women with a history of ICP.
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Table 3. Studies evaluating the effect of oral and transdermal hormone therapy 
on C-reactive protein with different progestins.
Study Estrogen +  progestin Dose/day ** months CRP
van Baal Estradiol 2mg O 1–3 ↑
1999 Estradiol +
Dydrogesterone (14days/monthly) or
Trimegestone (continuous)
2mg
10mg
0.5mg
O
O
O
1–3 ↑
Cushman Conjugated estrogens 0.625mg O 12–36 ↑
1999 Conjugated estrogens +
MPA (12days/monthly) or
MPA (continuous) or
micronized progesterone (12days/
monthly)
0.625mg
10mg
2.5mg
200mg
O
O
O
O
12–36 ↑
Wakatsuki Conjugated estrogens 0.625mg O 3 ↑
2002 Conjugated estrogens +
MPA (continuous)
0.625mg+ 
2.5mg
O
O
3 ↑
Conjugated estrogens +
MPA (continuous)
0.625mg+
5mg
O
O
3 →
Post Estradiol 50µg T 4–13 →
2002 Estradiol 1mg O 4–13 ↑
Estradiol +
Gestodene (continuous)
1mg+25µg O
O
4–13 →
Decensi 
2002
Estradiol +
MPA (12days/monthly)
50µg/d
10mg
T
O
6–12 ↑/→
Conjugated estrogens +
MPA (12days/monthly)
0.625mg
10mg
O
O
6–12 ↑
Skouby 
2002
Estradiol +
Cyproterone acetate (10/28 days) or
Cyproterone acetate (10/21 days) or
NETA (continuous) or
Levonorgestrel locally (spiral) or
Medroxyprogesterone acetate (14/91 
days)
2mg
1mg
1mg
1mg
20µg/24h
20mg
O
O
O
O
L
O
6–12
→
→
↑
↑
↑  / →
Silvestri
2003
Conjugated estrogens +
MPA (continuous)
0.625 mg 
2.5mg
O
O
3–6 ↑
Strandberg
2003
Estradiol 2mg (12 days) +
Estradiol 2mg + NETA 1mg (10 days) 
+
Estradiol 1mg (6 days)
O 6 ↑
Estradiol +
NETA (14days/monthly)
50µg
0.25mg
T
T
6 →
Ylikorkala
2002
Estradiol +
NETA (continuous)
2mg
1mg
O
O
6–12 ↑
**O=oral; T=transdermal treatment, L=local, spiral in the uterus
MPA=medroxyprogesterone acetate
NETA= noretisterone acetate
↑ = rise
→ = no change
↑ / → = rise during estrogen phase, but decrease during MPA phase
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AIMS OF THE STUDY
The present studies were aimed to clarify
1. the genetic background of intrahepatic cholestasis of pregnancy (ICP) in 
Finnish families
2. the incidence and risk factors for developing ICP
3. the effect of oral or transdermal postmenopausal hormone therapy on 
SHBG in women with a history of ICP
4. the effect of oral or transdermal postmenopausal hormone therapy on 
CRP in women with a history of ICP
5. liver and biliary diseases associated with ICP
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SUBJECTS AND METHODS
The studies were conducted with the approval of the Ethics Committee of the 
Department of Obstetrics and Gynecology of Helsinki University Central Hos-
pital in 1992–2004. Informed consent was obtained from the patients and con-
trols in studies I, III and IV after explaining the purpose, nature and possible 
risks of the study. Studies II and V were register-based epidemiological studies, 
which were conducted in collaboration with the National Research and Devel-
opment Centre for Welfare and Health in Helsinki.
1. Subjects
Sixty-nine pregnant women fulfi lling the established criteria for ICP attended 
the Department of Obstetrics and Gynecology in Helsinki University Cen-
tral Hospital during the years 1992–1993 (Study I) (Table 4). They were in-
terviewed for a family history of ICP. The clinical features were compared in 
Table 4. Number of patients and controls in each separate study.
Patients, controls by study Time 
period
Number
of subjects
Study I
a) Women with intrahepatic cholestasis of pregnancy 1992–1993 69
b) All delivered women 1992–1993 5 304
Study II
a) Women with a history of intrahepatic cholestasis of 
pregnancy
1987–2004 8 380
b) All delivered women 1987–2004 1 080 310
Study III, IV
a) Women with a history of intrahepatic cholestasis of 
pregnancy
2000–2001 20
b) Control women 2000–2001 20
Study V
a) Women with a history of intrahepatic cholestasis of 
pregnancy
1972–2000 10 504
b) Control women 1972–2000 10 504
The data for women in studies II and V were extracted from the Finnish Hospital Discharge Register. 
In studies I, III and IV women were collected from the patient register of the Department of Obstet-
rics and Gynecology Helsinki University Central Hospital.
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patients with a verifi ed family history of ICP (n=11) and in patients with no 
such history (n=58).
For the genetic analysis, 21 individuals (15 affected with ICP and 6 unaf-
fected) from two independently ascertained families were genotyped. In these 
two families ICP had occurred in three consecutive generations (Figure 5) 
(Study I).
Data from women with ICP (n=8380) were collected from the Finnish Hos-
pital Discharge Register in years 1987–2004 (Study II). During the study years 
two versions of the International Classifi cation of Diseases, ICD-9 and ICD-10, 
were used and all women with the diagnosis numbers 6467A (n=4289) or 026.6 
(n=3851) were enrolled. A proportion of women (n=240) had undergone their 
fi rst ICP pregnancy before 1987, but they had also experienced a pregnancy 
complicated with ICP during the study years.
To study the effect of postmenopausal HT on liver function we invited 20 
healthy postmenopausal women with a history of ICP (age 53-64 years) and 20 
age-matched controls to participate in study (Study III, IV). They had entered 
menopause approximately six years before the study. All ICP women had a 
history of at least one pregnancy complicated by ICP and 13 of them had expe-
rienced ICP repeatedly. On average, ICP had occurred 30 years (26–33 years) 
before the study. 
To evaluate the associations of liver and biliary diseases with ICP, we col-
lected data from 10 504 women with a history of ICP and the same number of 
matched controls with no such history  from the Finnish Hospital Discharge 
Register during the years 1987–2000 (Study V). Altogether 21008 women were 
included. Cumulative numbers of ICP women during these years are shown in 
Figure 6.
D2S2190 4  3
BSEP
D2S111 3  3
1  3
5  3
1  3
6  3
2  3
4  3
2  3
4  3
2  1
4  5
2  1
4  5
1  3
4  4
1  3
4  3
1  2
5  5
1  3
2  4
3  2
4  5
3  2
4  5
1  1
3  3
1  2
3  5
3  2
4  5
4  2
3  5
1  2
2  5
1  2
2  5
4  2
3  5
Figure 5. Two Finnish families with intrahepatic cholestasis of pregnancy in three pedi-
grees. The fl anking markers for bile salt export pump (BSEP) in chromsome 2q24 are 
shown and respective alleles in genotyped  individuals.
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2. Methods
2.1.1. Linkage analysis
The genetic mapping of a disease with linkage analysis is based on the proximity 
of the disease locus to other previously known loci (marker loci) on the same 
chromosome. These loci are said to be linked. During meiosis each chromo-
some replicates into two sister chromatids. Homologous parental chromosomes 
are then paired before division occurs. During this synapsis crossing over (or 
recombination) may happen. As a result, exchange of chromosome material 
between the two homologous parental chromosomes occurs. The likelihood of 
a crossing over occurring between two loci is dependent on the physical and 
genetic distance between the two, the likelihood being higher the greater the 
distance. Genetic distances are expressed as centiMorgans (cM). When two loci 
are 1cM apart, there is a 1% chance of recombination between these two loci 
per meiosis. One cM contains about one million base pairs in physical distance. 
When the disease locus is linked to a marker, whose inheritance can be studied in 
a family, the location of the disease gene can be deduced by studying the affected 
and unaffected individuals in the family. Linkage analysis tests the likelihood 
that the disease locus and the marker locus are inherited together by proximity 
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  1972-76   77-81   82-86   87-91  92-95  96-2000
  ICD-8  ICD-9  ICD-10
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0.49%
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0.87%
0.95%
Dark grey column: new ICP patient, age < 30 years 
Black column: new ICP patient, age ≥ 30 
White column: cumulative ratio of women, ICP diagnosed during earlier years
Light grey background: follow-up time during ICD-9 and-10
Figure 6. Cumulative numbers of women with intrahepatic cholestasis of pregnancy (ICP) 
during years 1972–2000 and during different International Classifi cation of Diseases ICD-
8, ICD-9 and ICD-10. Incidence of ICP for each time period is shown above the column.
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against the likelihood that they are inherited by chance. This is expressed by the 
logarithm of odds, or LOD, score. In different families the LOD scores are cal-
culated independently and can be combined. The power of the linkage analysis 
is stronger the larger the number of families with affected individuals, although 
many other factors also infl uence the power of the analysis.
 The same principal can be utilized to test the association of a known gene 
with a specifi c disease. In those cases markers fl anking the candidate locus or 
intragenic polymorphisms are used. 
2.1.2. Polymerase chain reaction
Polymerase chain reactions (PCR) with primers for markers on chromosomes 
2, 7 and 18 fl anking the BSEP, MDR3 and FIC1 loci, respectively, were per-
formed (Study I). The primer sequences were obtained from the GDB Human 
Genome Database. Buffers and AmpliTaq-Gold polymerase from Applied Bio-
systems (Roche, Branchburg, New Jersey, USA) were used during PCR. 
2.2. Hormone therapy protocol
The women were randomized to receive increasing doses of estradiol (E2) 
orally (2mg for 14 days and 4mg for 14 days of estradiol valerate, Progynova ®, 
Schering AG, Berlin, Germany) or transdermally from a patch (50µg/24h for 
14 days and 100µg/24h for 14 days of estradiol hemihydrate, FemSeven ®, Mer-
ck KgaA, Darmstadt, Germany) (Figure 7). The study was double-blinded in 
that during both treatments each woman took tablets (active or placebo) and 
used patches (placebo or active). At the end of the latter E2 period, medroxy-
Figure 7. Oral and transdermal estradiol followed by addition of MPA were given in 6-
week periods with placebo patches or placebo tablets, respectively. The subjects were ran-
domized to groups A (fi rst treatment oral, solid line) and B (fi rst treatment transdermal, 
hatsched line).
al E2 with placebo patch 
mg E2 4 mg E2       4 mg E2    2 mg E2     4 mg E2        4 mg E2 
      +10 mg MPA WASH-OUT    +10 mg MPA 
µg E2      100 µg E2    100 µg E2    50 µg E2     100 µg E2   100 µg E2 
  +10 mg MPA       +10 mg MPA 
ansdermal E2 with placebo tablets 
weeks    2 weeks      2 weeks             4 weeks     2 weeks    2 weeks      2 weeks 
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3. Statistical analyses
The incidences of ICP were age-adjusted using the direct-standardization tech-
nique and parous women during 1987–2004 as the standard population. Pois-
son regression analysis was used for the calculation of relative risks (RR). Rates, 
rate ratios and confi dence intervals were calculated using standard techniques 
(Study II, V). Because the analyses incorporated signifi cance tests for multiple 
but equally important endpoints, the p-values were Bonferroni-adjusted in or-
der to detect any possible bias. The software packages Survo MM (www.survo.
fi ) and SAS v9.1 (www.sas.com) were used in the data processing and analysis.
In the crossover design (Study III, IV), the possibility of a period effect was 
tested by the Mann-Whitney test, where we compared the differences between 
the periods in the two groups of patients (those beginning with oral and those 
beginning with transdermal E2); no period effect was detected. The possibility 
progesterone acetate (MPA) (10mg) (Lutopolar ®, Orion Pharma, Espoo, Fin-
land) was given for 14 days concomitantly with E2. After a four-week wash-out 
period, the subjects were crossed over to the other treatment. Blood samples 
for alanine (ALAT) and aspartate (ASAT) transaminases, bile acids, GT, SHBG, 
CRP, E1 and E2 were drawn after an overnight fast and serum separated with 
centrifugation was stored –20°C until analyzed.
2.3. Assays
The levels of liver transaminases and bile acids were measured using auto-ana-
lyzers. Estrone (E1), E2, SHBG and CRP were assayed with established meth-
ods, the details of which are given in Table 5.
Table 5. Characteristics of the assays used.
Factor Principle of assay Source of reacent Intra-assay 
CV
Inter-assay 
CV
Estrone Radioimmunoassay (RIA) Estron, Diagnostic 
Systems Laboratories, 
Sinsheim, Germany
<8% <10%
Estradioli Time-resolved 
fl uoroimmunoassay (FIA)
Delfi a, Wallac, Turku, 
Finland
<10% <10%
SHBG Time-resolved 
fl uoroimmunoassay (FIA)
AutoDelfi a, Wallac, 
Turku, Finland
<5% <3%
CRP Sensitive CRP 
Immunoentzymometric 
assay (IEMA)
Medix Biochemica, 
Kauniainen, Finland
<5% <5%
CV=Coeffi cient of variation, SHBG=sex hormone-binding globulin, CRP=C-reactive protein
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of a treatment-period interaction was investigated by the Mann-Whitney test, 
which compared the average responses to the two treatments. They were un-
related to the order of treatment. Therefore, women using HT orally or trans-
dermally were analyzed as separate groups. Because of the skewed distribution 
of SHBG, CRP, E2 and E1 data, non-parametric tests (Wilcoxon’s signed-rank 
test) were used for comparison. Non-parametric repeated measures ANOVA 
(Friedman test) were used to test variation among groups during treatment 
and Wilcoxon’s signed-rank test was used to test changes between the groups. 
Correlation analyses were performed using Spearman’s non-parametric cor-
relation coeffi cient. A two-tailed p<0.05 was accepted as the level of signifi -
cance.
36
RESULTS
Detailed results are given in the original publications and therefore, only the 
main results are summarized here.
1. Genetics
Positive family history for ICP was detected in 16% (11/69) of women. The 
levels of serum transaminases were higher in the familial than in the sporadic 
group (Table 6). Also the recurrence rate of ICP in familial cases (92%) was 
higher (p<0.05) as compared to that in sporadic cases (40%). ICP complicated 
14% and 43% of twin and triplet pregnancies, respectively. 
Table 6. Two highest alanine (ALAT) and aspartate (ASAT) aminotransferase 
and bile acid values (mean; SEM), and comparison of clinical features of int-
rahepatic cholestasis of pregnancy (ICP) between familial and sporadic cases 
(number; %).
Normal range Familial (n=11) Sporadic (n=58)
ASAT (U/l) 15–35 265.0 (66.0) 106.0 (9.0)**
ALAT (U/l) 10–40 348.7 (85.5) 190.5 (22.3)**
Bile acid (µmol/l) <6 29.4 (4.8) 32.0 (4.4)
Number of multiple 
pregnancies
149/5304 (2.8%) 3/11 (27%) 22/58 (38%)
Occurrence of ICP in 
previous pregnancies
11/12 (92%) 18/45 (40%)**
**p<0.05
Three known cholestasis genes were studied with markers fl anking each lo-
cus. Amplifi cation of microsatellite markers on chromosomes 2 (D2S2190, 
D2S111), 7 (D7S644, D7S2410) and 18 (D18S977, D18S849) fl anking the 
BSEP, MDR3 and FIC1 locus, respectively, was performed with polymerase 
chain reactions (PCR) (Study I). The distance between the markers D2S2190 
and D2S111 at the gene locus ABCB11 coding for the bile salt export pump is 
4.8cM. Multipoint linkage analysis gave positive LOD scores, maximum 1.12, 
over this region in family 2, but negative scores in family 1. Even though LOD 
score was positive it did not mean that the genes are linked. In haplotype analy-
sis (Figure 5), the affected individuals in family 1 had different alleles, suggest-
ing that mutations in this region are not associated with ICP in these women. 
The linkage analysis of the ABCB4 gene coding for MDR3 and the ATP8B1 
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gene coding for FIC1 gave negative LOD scores in both families. Additionally, 
two members from each of the two large families were screened for mutations 
in the ABCB4 gene by sequencing, but none were found.
2. Incidence and risk factors
The incidence of ICP in deliveries in Helsinki University Central Hospital 
(1.3%) (Study I) was slightly higher than that in the nation-wide study (1.0%) 
(Study II) and did not show any signifi cant changes during 1987–2004. For the 
register-based study, the crude and the age-adjusted incidences and the num-
bers of women with ICP during three 6-year periods are shown in Table 7. 
The risk of ICP correlated with rising maternal age. The risk in women > 39 
years of age was 3-fold higher than that in women < 30 years when adjusted 
for parity and multiple pregnancies (RR 2.98; 95% CI 2.73–3.25). The risk of 
ICP was also associated with maternal parity being higher in nulliparous com-
pared to multiparous women (incidence 1.24% versus 0.80%). Likewise, the 
risk of ICP was higher in multiple versus singleton pregnancies (RR 4.54; CI 
4.19–4.91). Multiple pregnancy was an independent risk factor, whereas there 
was a signifi cant interaction between maternal age and parity. Using parous 
women < 30 years of age as the reference group, the RR of ICP for nulliparous 
women was 1.34 (CI 1.26–1.42) in women < 30 years, 2.41 (CI 2.26–2.58) in 
women 30-39 years, and 5.52 (CI 4.73–6.44) in women > 39 years of age. The 
incidence was highest 16.9 % (CI 13.6–20.2) in the fi rst, multiple pregnancies 
of women > 39 years.
Table 7. The crude and age-adjusted incidences of ICP and number of preg-
nancies with ICP (n) during three 6-year period 1987–2004.
Periods 1987–1992 1993–1998 1999–2004
Crude incidence 0.95 % 0.87 % 1.02 %
Age-adjusted incidence 0.98 % 0.87 % 1.00 %
Pregnancy n n n
Singleton, nulliparous women 1 571 1 222 1 362
Singleton, parous women 1 835 1 701 1 818
Multiple pregnancy, nulliparous women 116 131 120
Multiple pregnancy, parous women 87 116 106
Total number of ICP pregnancies 3 609 3 170 3 406
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3. The effect of hormone therapy on sex hormone-binding 
globulin
Oral and transdermal E2 administration was not accompanied by signifi cant 
changes in levels of liver transaminases or bile acids. The levels fl uctuated but 
remained within the normal range in each subject.
Oral E2 therapy increased liver SHBG production in women, with and with-
out a history of ICP, after two weeks of treatment (Table 8). In the ICP group, 
SHBG concentrations increased during 2mg and 4mg doses of E2 daily by 42% 
and 121% and in control women by 67% and 171%, respectively. The response 
of SHBG to increasing E2 was blunted in the ICP group (median rise SHBG 38.2 
nmol/l) compared to controls (median 59.4 nmol/l) (p=0.006). The addition 
of MPA was associated with signifi cant decreases in SHBG levels both in ICP 
(14%) and control women (16%). In the control group, the SHBG responses 
correlated positively with E2 during weeks 0–2 (r=0.66, p=0.002), weeks 0–4 
(r=0.49, p=0.03) and weeks 0–6 (r=0.51, p=0.02) whereas in ICP women such 
a correlation existed only during weeks 0-4 (r=0.63, p=0.003). Increases in E2 
concentrations did not differ between the ICP and control women. 
Transdermal E2 with higher dose (100µg/day) raised SHBG concentration 
only in the control group (Table 9). Addition of MPA orally to the transdermal 
regimen reduced SHBG production in both groups.
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Table 8. Responses from baseline of sex hormone-binding globulin (SHBG)(nmol/
l) and C-reactive protein (CRP)(mg/l) (median, 95% confi dence interval) to 
oral estradiol (E2) therapy alone and in combination with medroxyproges-
terone acetate (MPA)(10mg/day) in women with a history of intrahepatic 
cholestasis of pregnancy (ICP) and control women.
E2 dose/day ∆ p E2 + MPA ∆ p
2 weeks 2mg +2weeks 4mg weeks 0–2 vs 
weeks 0-4
+2weeks4mg 
+MPA 10mg
weeks 0–4 vs 
weeks 0-6
SHBG
ICP
(n=20)
25 (10–38) 62 (48–106) p<0.001 66 (34–71) p=0.010
Control 
(n=19)
30 (24–56) 81 (57–103) p<0.001 57 (44–90) p<0.001
CRP
ICP 
(n=20)
0.2 (0.1–1.1) 0.6 (0.3–1.6) p=0.020 0.4 (0.2–1.1) NS
Control 
(n=19)
0.4 (0.1–0.9) 0.7 (0.3–2.4) p=0.020 0.8 (–0.3–1.3) NS
∆ p= signifi cance to the responses
Table 9. Responses from baseline of sex hormone-binding globulin (SHBG)(nmol/
l) and C-reactive protein (CRP)(mg/l) (median, 95% confi dence interval) to 
transdermal estradiol (E2) therapy alone and in combination with medroxy-
progesterone acetate (MPA)(10mg/day) in women with a history of intrahe-
patic cholestasis of pregnancy (ICP) and control women.
E2 dose/day ∆ p E2 + MPA ∆ p
2 weeks 50µg/day +2 weeks +100µg/
day
weeks 0–2
versus 
weeks 0–4
+2 weeks +100µg/
day +MPA 10mg
weeks 0–4 
versus weeks 
0–6
SHBG
ICP 
(n=20)
–0.4 (–3.4–3.9) 3.7 (–1.6–6.2) NS –6.6 (–17 – –2.0) p=0.003
Control 
(n=19)
–1.5 (–8.9–4.7) 3.0 (–2.0–12) p=0.020 –9.5 (–16 – – 2.3) p<0.001
CRP
ICP 
(n=20)
–0.2 (–0.8–0.2) –0.02 (–0.9– 0.4) NS –0.2 (-0.4–0.4) NS
Control 
(n=19)
–0.03 (–0.1–0.2) 0.02 (–0.2–0.9) NS –0.2 (–0.5–0.1) NS
∆ p=signifi cance to the responses
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4. The effect of hormone therapy on C-reactive protein
The levels of CRP rose within two weeks during oral E2 use. There were no dif-
ferences in CRP rise during oral 2mg and 4mg estradiol dose between women 
with and without a history of ICP. When both women with and without ICP 
history were analyzed together the rise in CRP was dose-dependent (49% and 
91%) (Table 8) and the changes in serum concentrations of CRP and E2 cor-
related positively (r=0.326, p=0.007). The administration of MPA during the 
last two weeks with higher E2 dose had no effect further on CRP production 
(which was already stimulated by oral E2).
Transdermal E2 had no effect on the CRP production in either group al-
though the dose was increased to 100µg/day. The administration of MPA to 
transdermal regimen had no effect on CRP (Table 9).
5. Associated liver and biliary diseases
Several liver and biliary diseases were associated with a history of ICP (Table 
10). The rate ratio for non-alcoholic cirrhosis with liver fi brosis was 8.2 (CI 
1.9–35.5) and for PBC alone 5.8 (CI 0.7–48). There were six cases of PBC in 
the ICP group, but none in the control group. A history of ICP was associ-
ated with hepatitis C, and with non-specifi c hepatitis (including autoimmune 
hepatitis).
The incidence of cholecystitis and cholelithiasis was almost fourfold higher 
in ICP women with rate ratio 3.7 (CI 3.2–4.2). In an age-group analysis it was 
clearly seen that women with ICP had gallstones at a younger age than controls. 
Non-alcoholic pancreatitis was more common in ICP patients than in controls 
(3.2, CI 1.7–5.7), whereas the rate ratio for alcohol-induced pancreatitis was 
not signifi cantly different in patient and controls.
Table 10. Diseases of the liver and biliary system in women with a history of 
intrahepatic cholestasis of pregnancy (ICP) and in the control women. Rate 
ratio (cases/controls) and 95% confi dence interval (CI) is shown.
Disease ICP
(n=10 504)
Control
(n=10 504)
Rate/ 
ratio
95% CI p
Hepatitis C and non-A-non-B 29 8 3.5 1.6–7.6 <0.001
Hepatitis, non-specifi c 26 6 4.2 1.7–10.2 <0.001
Cirrhosis, non-alcoholic 17 2 8.2 1.9–35.5 <0.050
Cholelithiasis and cholecystitis 965 260 3.7 3.2–4.2 <0.001
Biliary system disorders 45 15 2.9 1.6–5.2 <0.001
Non-alcoholic pancreatitis 46 14 3.2 1.7–5.7 <0.001
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DISCUSSION
Intrahepatic cholestasis of pregnancy (ICP) affects approximately 1% of preg-
nancies in Finland (Laatikainen et al 1984), and is probably the most common 
intrahepatic cholestatic condition world-wide. The relative hepatic incapacity 
to metabolize large amounts of pregnancy-related steroids is one of the ma-
jor contributing factors (Reyes 1993), but still the exact etiology has remained 
unknown. It has been noted that ICP occurs in families suggesting genetic 
susceptibility (Holzbach et al 1983, Hirvioja et al 1993). Recently, the genetic 
backgrounds of several types of progressive familial cholestasis were identifi ed 
(Jacquemin 2001). This has raised interest in the possible molecular genetic 
cause of ICP as well. 
In a genetic isolate the frequency of certain genetic variants and mutations 
may be high due to geographical enrichment. In Finland this has been shown 
both for alleles predisposing to common, complex diseases (Vuorio et al 2001) 
and mutations causing less common single gene disorders (Aittomäki et al 
1995). As ICP may behave as a single gene disorder in some families but as a 
complex trait in most cases, it should be possible to study both of these situa-
tions in the Finnish population. To elucidate the clinical picture and heredity 
of ICP we studied a series of 69 patients from whom detailed family history 
of ICP was collected. To study the genetic background of ICP we performed 
molecular genetic studies to fi nd the possible genes behind ICP in two Finnish 
families. 
Moreover, we wanted to determine the incidence of ICP, possible risk factors 
and associated liver and biliary diseases in Finland. For that purpose the rather 
uniform diagnosis of ICP and high standard register gave an excellent oppor-
tunity. We collected patients and controls from the nation-wide data base, the 
Finnish Hospital Discharge Register. In register-based studies biases may arise 
from case-control collection and this may affect the results. To avoid this bias 
the controls and patients were matched for age as well as time and place of 
delivery.  The personal identifi cation number, which was used as a linkage key, 
excludes the possibility of a double enrollment of the same individual. The va-
lidity of the Finnish Hospital Discharge Register has been evaluated in several 
studies. Virtually all inpatient hospital care periods in Finland are recorded in 
the register because the reporting is compulsory. The accuracy of most vari-
ables utilised in this study (personal and hospital ID-numbers, age, sex, and 
dates of admission and discharge) is at least 95%. The recorded main diagnosis 
is typically consistent (about 95%) with the medical record and for the subsidi-
ary diagnoses the consistency is also good. (Mäkikyrö et al 1998, Leppälä et al 
1999, Gissler et al 2004, Pajunen et al 2005).
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Finally, we studied the effects of oral and transdermal HT on the produc-
tion of SHBG and CRP. Liver dysfunction, even if subclinical, may have an 
effect on the protein production. The study design, a double-blind prospective 
cross-over study on 40 postmenopausal women, enabled the true comparison 
of the effects of oral and transdermal HT on SHBG and CRP in women with 
and without a history of ICP. 
Incidence, risk factors and genetic background of ICP
The incidence of ICP was 1.1% in the Helsinki University Central Hospital in 
the 1970’s and 1980’s (Laatikainen et al 1984). In our hospital-based series the 
incidence of ICP was 1.3% in the 1992. A somewhat lower incidence (0.54%) 
was reported from Kuopio University Hospital in 1990 (Heinonen et al 1999) 
but that study had excluded all multiple pregnancies, which predispose to this 
disease. In the present nationwide study ICP occurred in 0.94% of pregnan-
cies and this rate did not change markedly during 1987-2004. An unchanged 
incidence of ICP supports the idea that genetic predisposition could be one 
etiologic factor. However, as only inpatient care is recorded in our register the 
incidence of ICP we report is the minimum incidence. It is possible that some 
patients with ICP may have been treated as outpatients and were not included 
in our study. Moreover, some patients could be lost due to non-reporting of the 
diagnosis, because this risk appears higher for secondary diagnosis, while the 
fi rst diagnosis is known to be more reliable (Sund 2003, Gissler et al 2004).
We found that multiple pregnancy predisposes to the development of ICP, 
as has been shown in small series (Laatikainen et al 1984, Gonzalez et al 1989, 
Glantz et al 2004). The hospital-based study showed a higher risk of ICP (14% 
of twin pregnancies) than the register-based study (4.0%). 
As a novel fi nding we present strong evidence that advanced maternal age 
predisposes to ICP. The risk of ICP showed a positive correlation with mater-
nal age and is 3-fold higher in women over 39 years of age than in those under 
30 years. The risk was further enhanced by nulliparity. These fi ndings may ex-
plain, at least in part, why an elevated risk of ICP (RR 3.8) has been found in 
in-vitro-fertilization (IVF) pregnancies (Koivurova et al 2002). Women under-
going IVF are typically older, nulliparous women.
We demonstrate that ICP is familial in 16% and sporadic in 84% of cases. 
The background of ICP may actually differ between these two groups of pa-
tients, and this is also suggested by the differences in the clinical features such 
as signifi cantly higher levels of transaminases and higher rate of recurrence in 
familial cases. Recently the genetic backgrounds of several types of cholesta-
sis, including PFIC types 1, 2, and 3 with mutations in ATP8B1, ABCC11, and 
ABCB4, respectively, have been identifi ed. The possible association of ICP with 
some of these genes was initially suspected, because same heterozygous moth-
ers of children affected with PFIC3 had experienced ICP during pregnancy 
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(Jacquemin 2001). Although autosomal dominant inheritance has been sug-
gested, it is uncommon to fi nd large families with many females affected with 
ICP.  We were able to study two such families in whom ICP had occurred in at 
least 15 individuals in 3 generations (Figure 6).  However, none of the above 
mentioned cholestasis genes were found to be implicated in ICP etiology in 
our study.
Hormone use and liver proteins
Oral and transdermal HT was well tolerated during this short study with in-
creasing doses of E2. Liver transaminase activities remained within normal 
ranges in women with a history of ICP and controls. This can be seen as evi-
dence that the liver can metabolize both oral and transdermal E2 normally in 
women with a history of ICP.
Postmenopausal oral HT has shown to increase the production of SHBG 
(Stomati et al 1996, Serin et al 2001, Samsioe 2002). Women with a history of 
ICP were characterized as having normal levels of SHBG before the initiation 
of HT. The levels of SHBG rose with increasing doses of E2 in both women 
with and without a history of ICP. This must be a refl ection of the stimulated 
synthesis of this protein in the liver. Compared to control women, the response 
of SHBG to oral E2 was blunted in ICP women. Because no data imply that 
ICP should affect the degradation of SHBG, our data suggest that it is an in-
born feature of these women to have a suppressed response of SHBG to oral es-
trogen. In theory, these women may therefore become exposed to higher levels 
of free estrogen during the use of oral E2, and this effect may have both positive 
(e.g. bone) and negative (e.g. breast, gallstones and cardiovascular) effects. As 
transdermal E2 does not stimulate the synthesis of SHBG the route of estrogen 
administration may have an important role. The higher dose of transdermal E2 
and oral MPA induced decreases in SHBG concentrations. This may be medi-
ated in part through a rise in insulin-like growth factor 1 (IGF-1), which has 
been shown to decrease SHBG production (Kalme et al 2003). High doses of 
MPA have been shown to increase the production of IGF-1 (Saaresranta et al 
2002). 
Long-term oral postmenopausal HT has been shown to be associated with 
elevated levels of CRP (van Baal et al 1999, Post et al 2002, Ylikorkala et al 
2002, Silvestri et al 2003). This rise may account for the lack of effect of HT in 
primary (Manson et al 2003) and secondary (Hulley et al 1998) prevention of 
ischemic cardiac events.
Oral E2 raised the serum concentrations of CRP within two weeks both in 
women with a history of ICP and controls, whereas transdermal HT had no ef-
fect. This is in accordance with previous studies (van Baal et al 1999, Post et al 
2002, Ylikorkala et al 2002, Silvestri et al 2003). We could demonstrate that the 
rise in CRP was E2 dose-dependent, although it is possible that some of this ef-
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fect could be due to a prolonged effect of the preceding 2mg treatment as pre-
viously suggested (van Baal et al 1999). The increases in CRP concentrations 
were related to the rises in E2 only during oral use. Our data also show that the 
effect of oral E2 on CRP vanishes totally in four weeks.This supports the role 
of the liver in estrogen-induced elevation of CRP concentrations. We did not 
study the effect of HT on IL-6, which is suggested to be the primary stimulating 
factor for CRP synthesis in infl ammatory reactions (Straub et al 2000), but it 
has been shown that this cytokine is not increased during oral HT use (Lakoski 
et al 2005). It is also known that adiposity is correlated with higher CRP levels 
without HT (Barinas-Mirchell et al 2001). Obese postmenopausal women, due 
to higher aromatization in fat tissue (Ruggiero et al 2002, Tapanainen 2003), 
have higher E1 concentrations and this might be one explanation for CRP el-
evation in obese women. On the other hand, both human intra-abdominal 
and subcutaneous abdominal fat is known to produce IL-6 (Fried et al 1998). 
Of course we must take into account that the highest transdermal dose was 
100µg/day, and we do not know if higher doses of E2 would have stimulated 
CRP production.
It has also been thought that the rise in CRP during HT could be a sign of 
a proinfl ammatory effect of estrogen which may accelerate atherosclerosis and 
vascular occlusion (Lagrand et al 1999), yet most recent data do not uniformly 
support this hypothesis (Lakoski et al 2005). Anyway, our data can be seen as 
evidence that women with a history of ICP can use HT safely, both orally and 
transdermally, at least as it concerns liver function.
Consequences of ICP on liver and biliary tract
No later liver consequences, except for the risk for cholelithiasis, have been es-
tablished for ICP and ICP has been considered to be specifi c to the pregnancy. 
Our study did not support this. Cirrhosis was more common in women with a 
history of ICP. Of course we could not exclude with full certainty the possibil-
ity that these liver diseases could have preceded the onset of ICP subclinically, 
because these diseases may exist in a mild form and remain undiagnosed dur-
ing pregnancy. We also found increased incidence of hepatitis C infection in 
ICP patients than in the controls, while there was no difference in the risk of A 
and B hepatitis. This was in line with the only previous study from Italy (Lo-
catelli et al 1999), although the diagnostic criteria for ICP in the Italian study 
were not entirely similar to ours. It has been suggested that the hepatitis C virus 
could down-regulate the expression of the transporter MRP2 and this could 
cause the hepatocyte damage (Hinoshita et al 2001). The situation may re-
semble that in Dubin-Johnson syndrome, which is caused by mutations in the 
MRP2 gene. Like ICP patients, patients with Dubin-Johnson syndrome may 
develop jaundice during the intake of high-dose oral contraceptives. (Pauli-
Magnus et al 2005). A similar mechanism could trigger ICP, although we could 
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not demonstrate a connection between ICP and diseases of bilirubin metabo-
lism in our study.
We could also confi rm that the risk of cholelithiasis and cholecystitis was 
elevated in women with a history of ICP. Mutations in the genes coding pro-
teins MDR3 and BSEP have been associated to cholelithiasis (Jacquemin 2001, 
Rosmorduc et al 2003, van Mil et al 2005) We regard this higher rate as a true 
consequence of ICP, although a more frequent use of ultrasound examination 
in women with ICP during pregnancy may cause bias: asymptomatic patients 
with gallstones become more often detected in ICP group. It was also shown 
that women with ICP develop gallstones at a much younger age than controls. 
Both endogeneous and exogeneous estrogens and perhaps progestins may have 
a role in this (Dowling 2000, Simon et al 2001, Cirillo et al 2005). Gallstones 
and alcohol abuse are the most important causes of pancreatitis (van Brumme-
len 2003). Cholelithiasis may explain the higher frequency of pancreatitis (not 
alcohol-induced). However, the ATP8B1 gene is strongly expressed in extrahe-
patic tissues such as pancreas, small intestine and kidney (Pauli-Magnus et al 
2005). The presence of diarrhea and pancreatitis in patients with PFIC1 suggest 
a role in extrahepatic tissues. Finally, a genetic factor connecting cholelithiasis 
with ICP are mutations in the ABCB4 gene (coding MDR3), which have been 
found in patients with gallstones and in patients with ICP (Jacquemin et al 
2001, Rosmorduc et al 2001). To resolve the causes of associations between ICP 
and these diseases, further studies are clearly needed.
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CONCLUSIONS
1. ICP was familial in at least 15% of patients and in some families showed 
autosomal dominant inheritance. The disease mechanisms in sporadic and 
familial cases might not be entirely similar as there were differences in the 
phenotypes between the two groups. Mutations in three genes (ABCB4, 
ABCB11 and ATP8B1) regulating bile acid transport were not encountered 
in two Finnish families with ICP.
2. The incidence of ICP in Helsinki University Central Hospital in 1992–1993 
was 1.3% and ICP recurred in 92% of familial and in 40% of sporadic cases. 
In a nationwide study the incidence of ICP was slightly smaller (1.0%) and 
remained stable during the years 1987–2004.
3. Maternal age, parity, and multiple pregnancy were all risk factors for ICP. 
The recognition of these allows identifi cation of special risk pregnancies.
 
4. The livers of women with a history of ICP tolerated well the increasing doses 
of estradiol, both orally and transdermally, although the response of SHBG 
was slightly blunted during the oral regimen. Likewise, the liver of these 
women could increase the synthesis of CRP in a dose-dependent manner 
in response to oral estradiol already within two weeks; this response van-
ished in four weeks after the cessation of treatment. The activities of liver 
transaminases remained within the normal range. Transdermal estradiol 
had no effect on liver CRP or SHBG.
5. Women with a history of ICP were at a higher risk of some other liver and 
biliary diseases including non-alcoholic cirrhosis, non-specifi c hepatitis, 
hepatitis C, cholelithiasis and cholecystitis and pancreatitis in their later 
life.
6. Clinicians should inquire as to the history of ICP because it may have an 
infl uence on the health of a woman. Further studies are needed to resolve 
whether the women at risk of subsequent liver diseases could be identifi ed 
already during an ICP pregnancy. 
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